Frytak S, Shaw E G, Jett J R, Richardson R L, Foote R L, Creagan E T, Eagan R T, Su J Q
Mayo Clinic, Rochester, Minnesota, USA.
Am J Clin Oncol. 1996 Apr;19(2):193-8. doi: 10.1097/00000421-199604000-00022.
Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease,96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a "limited" status. with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.
60例患者，其中29例为局限性疾病，31例为广泛性疾病，接受了以顺铂为基础的静脉化疗方案，并在适用时接受了后续的超分割胸部放射治疗（HTRT）。在局限性疾病患者中，缓解率为100%（76%为完全缓解）；中位生存期为26.5个月；1年和2年生存率分别为90%和55%。在广泛性疾病患者中，96%有反应（36%为完全缓解），中位生存期为12.0个月，1年和2年生存率分别为48%和29%。35%的广泛性疾病患者分期降为“局限性”状态，中位生存期为20.3个月。分别有25%和7%的患者出现IV级白细胞减少和血小板减少，1例患者死于放射性肺炎。在本研究的限制范围内，以顺铂为基础的静脉化疗和HTRT似乎是治疗小细胞肺癌的一种安全有效的方案。
